XML 29 R52.htm IDEA: XBRL DOCUMENT v2.4.1.9
LICENSING AGREEMENTS (Details) (Viral Therapies Licensing Agreements [Member], USD $)
Dec. 31, 2014
Within 30 days of commencement of Phase I/II clinical trial [Member]
 
Business Acquisition [Line Items]  
Milestone payment $ 50,000admp_MilestonePayment
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= admp_ViralTherapiesLicensingAgreementsMember
/ admp_MilestonePaymentTypeAxis
= admp_MilestonePhaseIandIIClinicalTrialMember
Within 30 days of commencement of a separate Phase II trial as required by the FDA [Member]
 
Business Acquisition [Line Items]  
Milestone payment 50,000admp_MilestonePayment
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= admp_ViralTherapiesLicensingAgreementsMember
/ admp_MilestonePaymentTypeAxis
= admp_MilestonePhaseIIClinicalTrialMember
Within 30 days of commencement of a Phase III trial [Member]
 
Business Acquisition [Line Items]  
Milestone payment 300,000admp_MilestonePayment
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= admp_ViralTherapiesLicensingAgreementsMember
/ admp_MilestonePaymentTypeAxis
= admp_MilestonePhaseIIIClinicalTrialMember
Within 30 days of submission of a biological license application or a new drug application with the FDA [Member]
 
Business Acquisition [Line Items]  
Milestone payment $ 500,000admp_MilestonePayment
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= admp_ViralTherapiesLicensingAgreementsMember
/ admp_MilestonePaymentTypeAxis
= admp_MilestoneFDAApplicationMember